Oxford BioTherapeutics is Pioneering the Discovery of Novel Oncology Targets for Solid Tumours

We bring 20 years of innovation to the ADC and TCE field. In addition to our own, proprietary pipeline of ADC and TCE candidates we have a number of partnerships and collaborations that leverage our OGAP®-Verify technology.